Stay updated on Sparsentan in IgA Nephropathy: Clinical Trial
Sign up to get notified when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.

Latest updates to the Sparsentan in IgA Nephropathy: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedPublications section now states that PubMed publications are automatically filled, and the page revision is updated to v3.3.2.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoval of an administrative funding-status notice from the page. The study details, eligibility criteria, primary and secondary outcomes, and listed locations remain unchanged.SummaryDifference0.1%

- Check34 days agoChange DetectedNo significant changes were detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.2%

- Check63 days agoChange DetectedAdded a site operation notice, introduced a new disease resource (IgA glomerulonephritis), and updated revision to v3.2.0 while removing v3.1.0.SummaryDifference2%

- Check70 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Sparsentan in IgA Nephropathy: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.